Latest research on Erbitux

Epidermal growth factor receptor binding FAB. Cetuximab is composed of the Fv (variable; antigen-binding) regions of the 225 murine EGFr monoclonal antibody specific for the N-terminal portion of human EGFr with human IgG1 heavy and kappa light chain constant (framework) regions.

Erbitux dosage

Whole cell ELISA showed that the recombinant wild-type EGFR mAb exhibited dose-dependent binding to A431 cells, comparable to Erbitux (Figure 1). [source, 2014]
Out of 12 drugs (Paclitaxel, Carboplatin, Gemcitabine, Gefitinib, Erlotinib, Afatinib, Sunitinib, Dasatinib, Bosutinib, Lapatinib, Erbitux and METF) (Table S1), we found METF modestly inhibited the growth of HCC4006, NCI-H1975 and HCC95 monolayer cells in a dose-dependent manner at the 72hrs time point, as revealed by CellTiter-Glo cell viability assay (Figure 2A). [source, 2014]
The patients were treated by BMS-582664 (brivanib alaninate) in combination with full-dose cetuximab (Erbitux), a monoclonal antibody targeting epidermal growth factor receptor. [source, 2014]
To confirm the synergistic effect of CCN2 and anti-EGFR monoclonal antibody (Erbitux) in repressing lung cancer, we tested the survival of CL1-5 receiving Erbitux and different doses of rCCN2 in attachment condition. [source, 2013]
Tumor accumulation, expressed as injected dose per gram tissue of CD44v6 Ab after 8 days, was not different from previous studies performed with Erbitux after 24 h [25]. [source, 2012]
The key to this method is in the separate administration of Doxil (Doxorubicin encapsulated into 85 nm liposomes) at significantly reduced doses and the conjugates of gold NPs with C225 antibody (Erbitux) (Figure 1A). [source, 2012]
The delivered relative dose intensity was 85.3% for CPT-11, 93.2% for LOHP, 83.2% for 5-FU, 94.0% for LV and 94.4% for Erbitux of the protocol-planned doses. [source, 2012]
Six patients (one woman and five men) with advanced gastrointestinal malignancies were treated by BMS-582664 (brivanib alaninate) in combination with full-dose cetuximab (Erbitux), a monoclonal antibody targeting EGFR. [source, 2011]
Data from the recent EVEREST trial (Evaluation of Various Erbitux Regimens by Means of Skin and Tumor Biopsies), involving patients with no or limited skin reactions, suggest that individualized dose titration based on the occurrence and severity of rash might be used to improve treatment response to EGFR inhibitors102. [source, 2010]
A phase III randomized clinical trial evaluated the addition of cetuximab (Erbitux TM) to high dose radiation in patients with locoregionally advanced SCCHN and demonstrated a statistically significant prolongation of OS in the combined modality arm versus radiation alone [45,46]. [source, 2010]